Niamh B. McNamara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Niamh B. McNamara has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Akiko Uyeda
Departments of Molecular Pharmacology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Japan
2 shared publicationsAlana Hoffmann
UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK
2 shared publications- Anna Williams
UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK
2 shared publications - Barry W. McColl
University of Edinburgh
2 shared publications Carsten Dittmayer
Department of Neuropathology and Neurocure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany
2 shared publications- Clare Pridans
Institution for Regeneration and Repair, University of Edinburgh, Edinburgh, UK
2 shared publications
Latest Publications
- Open Access
- 3 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8021) , E11
Author Correction: Microglia regulate central nervous system myelin growth and integrity
- 3 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8021) , E11
Open AccessAuthor Correction: Microglia regulate central nervous system myelin growth and integrity
- Top Cited PapersOpen Access
- 14 December 2022
- Published by Springer Nature in Nature
- Vol. 613 (7942) , 120-129
Microglia regulate central nervous system myelin growth and integrity
Myelin is required for the function of neuronal axons in the central nervous system, but the mechanisms that support myelin health are unclear. Although macrophages in the central nervous system have been implicated in myelin health1, it is unknown which macrophage populations are involved and which aspects they influence. Here we show that resident microglia are crucial for the maintenance of myelin health in adulthood in both mice and humans. We demonstrate that microglia are dispensable for developmental myelin ensheathment. However, they are required for subsequent regulation of myelin growth and associated cognitive function, and for preservation of myelin integrity by preventing its degeneration. We show that loss of myelin health due to the absence of microglia is associated with the appearance of a myelinating oligodendrocyte state with altered lipid metabolism. Moreover, this mechanism is regulated through disruption of the TGFβ1–TGFβR1 axis. Our findings highlight microglia as promising therapeutic targets for conditions in which myelin growth and integrity are dysregulated, such as in ageing and neurodegenerative disease2,3.
- 14 December 2022
- Published by Springer Nature in Nature
- Vol. 613 (7942) , 120-129
Top Cited PapersOpen AccessMicroglia regulate central nervous system myelin growth and integrity
Myelin is required for the function of neuronal axons in the central nervous system, but the mechanisms that support myelin health are unclear. Although macrophages in the central nervous system have been implicated in myelin health1, it is unknown which macrophage populations are involved and which aspects they influence. Here we show that resident microglia are crucial for the maintenance of myelin health in adulthood in both mice and humans. We demonstrate that microglia are dispensable for developmental myelin ensheathment. However, they are required for subsequent regulation of myelin growth and associated cognitive function, and for preservation of myelin integrity by preventing its degeneration. We show that loss of myelin health due to the absence of microglia is associated with the appearance of a myelinating oligodendrocyte state with altered lipid metabolism. Moreover, this mechanism is regulated through disruption of the TGFβ1–TGFβR1 axis. Our findings highlight microglia as promising therapeutic targets for conditions in which myelin growth and integrity are dysregulated, such as in ageing and neurodegenerative disease2,3.
- 25 April 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (9) , 3661-3669
Effect of Macronutrient Type and Gastrointestinal Release Site on PYY Response in Normal Healthy Subjects
Background & Aims Enteroendocrine L cells release satiety inducing hormones in response to stimulation by luminal macronutrients. We sought to profile the differential impact of macronutrient type and site of release on circulating concentrations of the L cell derived enteroendocrine hormone Peptide Tyrosine Tyrosine (1-36) (PYY). Materials & Methods Eight healthy volunteers were recruited to a randomised, double-blinded, six-way crossover study. At each visit, participants consumed a 500 kilocalorie drink containing either carbohydrate, protein or fat, in either gastric or small intestinal release formulations. Plasma PYY concentrations and hunger ratings were assessed over 3 hours after consumption of the test drink. Food intake was recorded thereafter at an libitum lunch. Results Microcapsular formulations targeting the distal small intestinal delivery of fat, but not carbohydrate or protein, markedly enhance PYY release relative to macronutrient delivery in gastric release formulations. Food intake at an ad libitum meal was lowest following consumption of the formulation releasing fat at the distal small intestine. Conclusion Targeting of fat to the distal small intestine in delayed release microcapsules enhances PYY release and is associated with reductions in food intake.
- 25 April 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (9) , 3661-3669
Effect of Macronutrient Type and Gastrointestinal Release Site on PYY Response in Normal Healthy Subjects
Background & Aims Enteroendocrine L cells release satiety inducing hormones in response to stimulation by luminal macronutrients. We sought to profile the differential impact of macronutrient type and site of release on circulating concentrations of the L cell derived enteroendocrine hormone Peptide Tyrosine Tyrosine (1-36) (PYY). Materials & Methods Eight healthy volunteers were recruited to a randomised, double-blinded, six-way crossover study. At each visit, participants consumed a 500 kilocalorie drink containing either carbohydrate, protein or fat, in either gastric or small intestinal release formulations. Plasma PYY concentrations and hunger ratings were assessed over 3 hours after consumption of the test drink. Food intake was recorded thereafter at an libitum lunch. Results Microcapsular formulations targeting the distal small intestinal delivery of fat, but not carbohydrate or protein, markedly enhance PYY release relative to macronutrient delivery in gastric release formulations. Food intake at an ad libitum meal was lowest following consumption of the formulation releasing fat at the distal small intestine. Conclusion Targeting of fat to the distal small intestine in delayed release microcapsules enhances PYY release and is associated with reductions in food intake.